Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$2.64 0.06 (2.29%)
2/9/2010 3:42 PM

Corcept Therapeutics, Inc. (CORT)

CAPS Rating:
*

A pharmaceutical company which is engaged in the development of drugs for the treatment of severe psychiatric and metabolic diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating CORT

Add Stock to Watchlist

What the Community Thinks

Total Members

36 Outperforms
21 Underperforms
 

All-Stars

9 Outperforms
9 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on CORT are also bullish on:

Members bearish on CORT are also bearish on:

Ticker Tags

Aggressive Growth (860), Healthcare (711), Defensive (1457), Pharmaceuticals (149), Micro Cap (4701), Growth (1902)
Suggest a tag

Corcept Therapeutics, Inc. At A Glance

Current Price: $2.64
Last Trade Time: 2/9/2010 3:42 PM
Open: $0.00
Previous Close: $2.58
Daily Range: $2.57 - $2.64
52-Week Range: $0.73 - $3.22
Volume: 15,098
Market Cap: $164.93M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

CORT VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for CORT

More Headlines...

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

Recs

2

Corcept Therapeutics, Inc. (CORT)

Avatar zzlangerhans (99.64) Submitted: 12/22/09 1:01 PM

Corcept continues to flog Corlux, its pipeline in a teacup. The stock continues to get diluted as the phase III study of Corlux in Cushing's syndrome approaches a topline data release in mid-2010. As there is minimal clinical data for efficacy in Cushing's to support the phase III study, I'm not goi...More

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 9 :   1 2 Next »

Show Pitch Replies

Recs

0

 (CORT)

Avatar tdoodler (95.41) Submitted: 1/27/10 10:05 AM : Underperform Start Price: $2.80 CORT Score: 4.07

Per GMX

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CORT)

Avatar Momentum21 (92.12) Submitted: 12/22/09 2:21 PM : Underperform Start Price: $2.59 CORT Score: -5.97

zz tip

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (CORT)

Avatar zzlangerhans (99.64) Submitted: 12/22/09 1:01 PM : Underperform Start Price: $2.61 CORT Score: -5.24

Corcept continues to flog Corlux, its pipeline in a teacup. The stock continues to get diluted as the phase III study of Corlux in Cushing's syndrome approaches a topline data release in mid-2010. As there is minimal clinical data for efficacy in Cushing's to support the phase III study, I'm not going to get my buffalo hump in a lather over it. The phase III study in psychotic depression is a joke, with obvious enrollment issues in the wake of multiple prior failures for the same indication.

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (CORT)

Avatar NoDoughBro (71.33) Submitted: 10/21/09 11:39 PM : Outperform Start Price: $2.33 CORT Score: 11.83

Gimme drugs...gimme drugs.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (CORT)

Avatar tiobueno (97.97) Submitted: 4/04/08 12:29 PM : Outperform Start Price: $3.56 CORT Score: -6.73

March 27, 2008 12:44 PM EDT

Corcept Therapeutics Inc. (Nasdaq: CORT) Director, Joseph Cook, bought 176,522 on 3/25 at $2.77, bringing his stake to 1,656,360 shares. In addition, Director, David Mahoney, bought 70,609 shares on 3/25 at $2.77, bringing his stake to 636,547 shares.

Corcept Therapeutics Incorporated develops drugs for the treatment of severe psychiatric and metabolic diseases. [LJ]

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 9 :   1 2 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackLadenburg 80.62 01/06/10 Outperform NS $2.99-11.71%-5.55%-6.16

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD04 312ms